US2007258963A1PendingUtilityA1

Mesenchymal stem cells expressing TNF-alpha receptors

59
Assignee: OSIRIS THERAPEUTICS INCPriority: Jan 13, 2006Filed: Jan 5, 2007Published: Nov 8, 2007
Est. expiryJan 13, 2026(expired)· nominal 20-yr term from priority
Inventors:Alla DanilkovitchDiane CarterAlicia TyrellSimon BubnicMichelle MarcelinoRodney Monroy
A61P 35/00A61P 29/00C12N 2501/25C12N 5/0662A61K 2035/122G01N 2333/525A61K 35/28C12N 5/0663
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Mesenchymal stem cells which express TNF-{acute over (α)} receptor Type I in an amount of at least 13 pg/10 6 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.

Claims

exact text as granted — not AI-modified
1 . A composition comprising mesenchymal stem cells wherein said mesenchymal stem cells express TNF-{acute over (α)} receptor Type I in an amount of at least 13 pg/10 6  cells.  
   
   
       2 . The composition of  claim 1  wherein said mesenchymal stem cells express TNF-{acute over (α)} receptor Type I in an amount of at least 15 pg/10 6  cells.  
   
   
       3 . The composition of  claim 2  wherein said mesenchymal stem cells express TNF-{acute over (α)} receptor Type I in an amount of at least 18 pg/10 6  cells.  
   
   
       4 . The composition of  claim 1  wherein said mesenchymal stem cells are human mesenchymal stem cells.  
   
   
       5 . The composition of  claim 1 , and further comprising an acceptable pharmaceutical carrier.  
   
   
       6 . A method of obtaining mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 6  cells, comprising: 
 obtaining at least one cell population including mesenchymal stem cells from at least one donor;    determining the amount of TNF-α receptor Type I expressed by the mesenchymal stem cells in each of said at least one cell population(s); and    selecting mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 6  cells.    
   
   
       7 . The method of  claim 6  wherein said selected mesenchymal stem cells express TNF-α receptor Type I in an amount of at least 15 pg/10 6  cells.  
   
   
       8 . The method of  claim 7  wherein said selected mesenchymal stem cells express TNF-α receptor Type I in an amount of at least 18 pg/10 6  cells.  
   
   
       9 . The method of  claim 6  wherein said mesenchymal stem cells are human mesenchymal stem cells.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.